Mylan (MYL) Unit Launches Generic Viramune Tabs
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nevirapine Tablets USP, 200 mg.
This product is the generic version of Boehringer Ingelheim's Viramune and is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection.
This product is the generic version of Boehringer Ingelheim's Viramune and is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Real and RE/MAX Holdings receive court approval for merger
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
